Brief: Coya Therapeutics Announces Pipeline Expansion Of Coya 302 To Include Frontotemporal Dementia To Parkinson’S And Amyotrophic Lateral Sclerosis
16/01/2024 13:17
Jan 16 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS ANNOUNCES PIPELINE EXPANSION OF COYA 302
TO
INCLUDE FRONTOTEMPORAL DEMENTIA AND PARKINSON’S DISEASE IN
ADDITION TO AMYOTROPHIC LATERAL SCLEROSIS
* COYA THERAPEUTICS INC - CASH RUNWAY GUIDANCE REMAINS INTO
2026
* COYA THERAPEUTICS INC - INTENDS TO FILE AN IND FOR COYA
302 FOR
TREATMENT OF ALS IN FIRST HALF OF 2024
* COYA THERAPEUTICS INC - INTENDS TO FILE IND FOR COYA 302
FOR
TREATMENT OF FTD BEFORE END OF 2024
Source text for Eikon: ID:nBw8MnQHDa
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)